Sodium Chloride


B. Braun Medical Inc.
Human Prescription Drug
NDC 0264-7802
Sodium Chloride is a human prescription drug labeled by 'B. Braun Medical Inc.'. National Drug Code (NDC) number for Sodium Chloride is 0264-7802. This drug is available in dosage form of Injection, Solution. The names of the active, medicinal ingredients in Sodium Chloride drug includes Sodium Chloride - .45 g/100mL . The currest status of Sodium Chloride drug is Active.

Drug Information:

Drug NDC: 0264-7802
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Sodium Chloride
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Sodium Chloride
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: B. Braun Medical Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Injection, Solution
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:SODIUM CHLORIDE - .45 g/100mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:INTRAVENOUS
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: NDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 09 Mar, 1988
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 17 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: NDA019635
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:B. Braun Medical Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:1807551
1807552
1807633
1807634
1807639
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:451W47IQ8X
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Increased Large Intestinal Motility [PE]
Inhibition Large Intestine Fluid/Electrolyte Absorption [PE]
Osmotic Activity [MoA]
Osmotic Laxative [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
0264-7802-0012 CONTAINER in 1 CASE (0264-7802-00) / 1000 mL in 1 CONTAINER09 Mar, 1988N/ANo
0264-7802-1024 CONTAINER in 1 CASE (0264-7802-10) / 500 mL in 1 CONTAINER09 Mar, 1988N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Sodium chloride sodium chloride sodium chloride sodium cation chloride ion water hydrochloric acid sodium chloride sodium chloride sodium chloride sodium cation chloride ion water hydrochloric acid

Indications and Usage:

Indications and usage these intravenous solutions are indicated for use in adults and pediatric patients as sources of electrolytes and water for hydration. 0.9% sodium chloride injection usp is indicated for extracellular fluid replacement, treatment of metabolic alkalosis in the presence of fluid loss and mild sodium depletion. 0.9% sodium chloride injection usp is also indicated for use as a priming solution in hemodialysis procedures and may be used to initiate and terminate blood transfusions without hemolyzing red blood cells. 0.45% sodium chloride injection usp is primarily a hydrating solution and may be used to assess the status of the kidneys, since more water is provided than is required for excretion of salt. it may also be used in the treatment of hyperosmolar diabetes where the use of dextrose is inadvisable and there is a need for large amounts of fluid without an excess of sodium ions. sodium chloride injections usp are also indicated as pharmaceutic aids and diluents f
or the infusion of compatible drug additives. refer to prescribing information accompanying additive drugs.

Warnings:

Warnings the administration of intravenous solutions can cause fluid and/or solute overload resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. the risk of dilutional states is inversely proportional to the electrolyte concentration. the risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentration. solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states in which there is sodium retention with edema. in patients with diminished renal function, administration of solutions containing sodium ions may result in sodium retention. infusion of isotonic (0.9%) sodium chloride during or immediately after surgery may result in excessive sodium retention. use the patient's circulatory system status as a guide.

General Precautions:

General clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation. significant deviations from normal concentrations may require tailoring of the electrolyte pattern, in these or alternative solutions. these solutions should be used with care in patients with hypervolemia, renal insufficiency, urinary tract obstruction, or impending or frank cardiac decompensation. extraordinary electrolyte losses such as may occur during protracted nasogastric suction, vomiting, diarrhea or gastrointestinal fistula drainage may necessitate additional electrolyte supplementation. additional essential electrolytes, minerals and vitamins should be supplied as needed. sodium-containing solutions should be administered with caution to patients receiving corticosteroids or corticotropin, or to other salt-re
taining patients. care should be exercised in administering solutions containing sodium to patients with renal or cardiovascular insufficiency, with or without congestive heart failure, particularly if they are postoperative or elderly. infusion of more than one liter of isotonic (0.9%) sodium chloride per day may supply more sodium and chloride than normally found in serum, and can exceed normal tolerance, resulting in hypernatremia; this may also cause a loss of bicarbonate ions, resulting in an acidifying effect. to minimize the risk of possible incompatibilities arising from mixing this solution with other additives that may be prescribed, the final infusate should be inspected for cloudiness or precipitation immediately after mixing, prior to administration and periodically during administration. do not use plastic containers in series connection. if administration is controlled by a pumping device, care must be taken to discontinue pumping action before the container runs dry or air embolism may result. if administration is not controlled by a pumping device, refrain from applying excessive pressure (>300mmhg) causing distortion to the container such as wringing or twisting. such handling could result in breakage of the container. these solutions are intended for intravenous administration using sterile equipment. it is recommended that intravenous administration apparatus be replaced at least once every 24 hours. use only if solution is clear and container and seals are intact.

Dosage and Administration:

Dosage and administration these solutions are for intravenous use only. dosage is to be directed by a physician and is dependent upon age, weight, clinical condition of the patient and laboratory determinations. frequent laboratory determinations and clinical evaluation are essential to monitor changes in blood glucose and electrolyte concentrations, and fluid and electrolyte balance during prolonged parenteral therapy. in the average adult, daily requirements of sodium and chloride are met by the infusion of one liter of 0.9% sodium chloride (154 meq each of sodium and chloride). there is no specific pediatric dose. the dose is dependent on weight, clinical condition and laboratory results. follow recommendations of appropriate pediatric reference text. (see precautions, pediatric use .) fluid administration should be based on calculated maintenance or replacement fluid requirements for each patient. 0.9% sodium chloride injection usp may also be administered intravascularly as a prim
ing fluid in hemodialysis procedures. when sodium chloride injections usp are used as diluents for infusion of compatible drug additives, refer to dosage and administration information accompanying additive drugs. some additives may be incompatible. consult with pharmacist. when introducing additives, use aseptic techniques. mix thoroughly. do not store. parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Contraindications:

Contraindications these solutions are contraindicated where the administration of sodium or chloride could be clinically detrimental.

Adverse Reactions:

Adverse reactions reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia. the physician should also be alert to the possibility of adverse reactions to drug additives. prescribing information for drug additives to be administered in this manner should be consulted. symptoms may result from an excess or deficit of one or more of the ions present in the solution; therefore, frequent monitoring of electrolyte levels is essential. hypernatremia may be associated with edema and exacerbation of congestive heart failure due to the retention of water, resulting in an expanded extracellular fluid volume. if infused in large amounts, chloride ions may cause a loss of bicarbonate ions, resulting in an acidifying effect. if an adverse reaction does occur, discontinue the infusion, evaluate the patient, instit
ute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.

Use in Pregnancy:

Pregnancy teratogenic effects pregnancy category c animal reproduction studies have not been conducted with sodium chloride injections usp. it is also not known whether sodium chloride injections usp can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. sodium chloride injections usp should be given to a pregnant woman only if clearly needed.

Pediatric Use:

Pediatric use safety and effectiveness of sodium chloride injections in pediatric patients have not been established by adequate and well controlled trials, however, the use of electrolyte solutions in the pediatric population is referenced in the medical literature. the warnings, precautions and adverse reactions identified in the label copy should be observed in the pediatric population.

Geriatric Use:

Geriatric use an evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Overdosage:

Overdosage in the event of a fluid or solute overload during parenteral therapy, reevaluate the patient's condition and institute appropriate corrective treatment.

Description:

Description each 100 ml of 0.9% sodium chloride injection usp contains: sodium chloride usp 0.9 g; water for injection usp qs ph: 5.6 (4.5–7.0) calculated osmolarity: 310 mosmol/liter ph adjusted with hydrochloric acid nf concentration of electrolytes (meq/liter): sodium 154 chloride 154 each 100 ml of 0.45% sodium chloride injection usp contains: sodium chloride usp 0.45 g; water for injection usp qs ph: 5.6 (4.5–7.0) calculated osmolarity: 155 mosmol/liter, hypotonic ph adjusted with hydrochloric acid nf concentration of electrolytes (meq/liter): sodium 77 chloride 77 sodium chloride injections usp are sterile, nonpyrogenic, isotonic and contain no bacteriostatic or antimicrobial agents. the formula of the active ingredient is: ingredient molecular formula molecular weight sodium chloride usp nacl 58.44 not made with natural rubber latex, pvc or dehp. the plastic container is made from a multilayered film specifically developed for parenteral drugs. it contains no plasticizers and exhibits virtually no leachables. the solution contact layer is a rubberized copolymer of ethylene and propylene. the container is nontoxic and biologically inert. the container-solution unit is a closed system and is not dependent upon entry of external air during administration. the container is overwrapped to provide protection from the physical environment and to provide an additional moisture barrier when necessary. addition of medication should be accomplished using complete aseptic technique. the closure system has two ports; the one for the administration set has a tamper evident plastic protector and the other is a medication addition site. refer to the directions for use of the container.

Clinical Pharmacology:

Clinical pharmacology sodium chloride injections usp provide electrolytes and are a source of water for hydration. they are capable of inducing diuresis depending on the clinical condition of the patient. sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid. chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis, impairment of fertility studies with sodium chloride injections usp have not been performed to evaluate carcinogenic potential, mutagenic potential or effects on fertility.

How Supplied:

How supplied sodium chloride injections usp are supplied sterile and nonpyrogenic in excel ® containers. the 1000 ml containers are packaged 12 per case; the 500 ml and 250 ml containers are packaged 24 per case. ndc ref size 0.9% sodium chloride injection usp (canada din 01924303) 0264-7800-00 l8000 1000 ml 0264-7800-10 l8001 500 ml 0264-7800-20 l8002 250 ml 0.45% sodium chloride injection usp (canada din 01927949) 0264-7802-00 l8020 1000 ml 0264-7802-10 l8021 500 ml exposure of pharmaceutical products to heat should be minimized. avoid excessive heat. protect from freezing. it is recommended that the product be stored at room temperature (25°c); however, brief exposure up to 40°c does not adversely affect the product.

Information for Patients:

Directions for use of excel® container caution: do not use plastic containers in series connection. to open tear overwrap down at notch and remove solution container. check for minute leaks by squeezing solution container firmly. if leaks are found, discard solution as sterility may be impaired. if supplemental medication is desired, follow directions below before preparing for administration. note : before use, perform the following checks: inspect each container. read the label. ensure solution is the one ordered and is within the expiration date. invert container and carefully inspect the solution in good light for cloudiness, haze, or particulate matter. any container which is suspect should not be used. use only if solution is clear and container and seals are intact. preparation for administration remove plastic protector from sterile set port at bottom of container. attach administration set. refer to complete directions accompanying set. to add medication warning: some addit
ives may be incompatible. to add medication before solution administration prepare medication site. using syringe with 18–22 gauge needle, puncture medication port and inner diaphragm and inject. squeeze and tap ports while ports are upright and mix solution and medication thoroughly. to add medication during solution administration close clamp on the set. prepare medication site. using syringe with 18–22 gauge needle of appropriate length (at least 5/8 inch), puncture resealable medication port and inner diaphragm and inject. remove container from iv pole and/or turn to an upright position. evacuate both ports by tapping and squeezing them while container is in the upright position. mix solution and medication thoroughly. return container to in use position and continue administration.

Package Label Principal Display Panel:

Principal display panel - 0.9 g/1000 ml container label 0.9% sodium chloride injection usp ref l8000 ndc 0264-7800-00 din 01924303 hk 22617 1000 ml excel ® container each 100 ml contains: sodium chloride usp 0.9 g; water for injection usp qs ph adjusted with hcl nf ph: 5.6 (4.5-7.0); calc. osmolarity: 310 mosmol/liter electrolytes (meq/liter): na + 154; cl – 154 sterile, nonpyrogenic. single dose container. do not use in series connection. for intravenous use only. use only if solution is clear and container and seals are intact. warnings: some additives may be incompatible. consult with pharmacist. when introducing additives, use aseptic techniques. mix thoroughly. do not store. recommended storage: room temperature (25°c). avoid excessive heat. protect from freezing. see package insert. do not remove overwrap until ready for use. after removing the overwrap, check for minute leaks by squeezing container firmly. if leaks are found, discard solution as sterility may be impaired. not made with natural rubber latex, pvc or dehp. rx only excel is a registered trademark of b. braun medical inc. b. braun medical inc. bethlehem, pa 18018-3524 usa 1-800-227-2862 www.bbraun.com in canada, distributed by: b. braun of canada, ltd. scarborough, ontario m1h 2w4 y94-003-229 ld-195-3 exp lot other 1000 ml container label l8000

Principal display panel - 0.9 g/500 ml container label 0.9% sodium chloride injection usp ref l8001 ndc 0264-7800-10 din 01924303 hk 22617 500 ml excel ® container each 100 ml contains: sodium chloride usp 0.9 g; water for injection usp qs ph adjusted with hcl nf ph: 5.6 (4.5–7.0); calc. osmolarity: 310 mosmol/liter electrolytes (meq/liter): na + 154; cl – 154 sterile, nonpyrogenic. single dose container. do not use in series connection. for intravenous use only. use only if solution is clear and container and seals are intact. warnings: some additives may be incompatible. consult with pharmacist. when introducing additives, use aseptic techniques. mix thoroughly. do not store. recommended storage: room temperature (25°c). avoid excessive heat. protect from freezing. see package insert. do not remove overwrap until ready for use. after removing the overwrap, check for minute leaks by squeezing container firmly. if leaks are found, discard solution as sterility may be impaired. not made with natural rubber latex, pvc or dehp. rx only excel is a registered trademark of b. braun medical inc. b. braun medical inc. bethlehem, pa 18018-3524 usa 1-800-227-2862 www.bbraun.com in canada, distributed by: b. braun of canada, ltd. scarborough, ontario m1h 2w4 y94-003-228 ld-137-3 exp lot other 500 ml container label l8001

Principal display panel - 0.9 g/250 ml container label 0.9% sodium chloride injection usp ref l8002 ndc 0264-7800-20 din 01924303 hk 22617 250 ml excel ® container each 100 ml contains: sodium chloride usp 0.9 g; water for injection usp qs ph adjusted with hcl nf ph: 5.6 (4.5–7.0); calc. osmolarity:310 mosmol/liter electrolytes (meq/liter): na + 154; cl – 154 sterile, nonpyrogenic. single dose container. do not use in series connection. for intravenous use only. use only if solution is clear and container and seals are intact. warnings: some additives may be incompatible. consult with pharmacist. when introducing additives, use aseptic techniques. mix thoroughly. do not store. recommended storage: room temperature (25°c). avoid excessive heat. protect from freezing. see package insert. do not remove overwrap until ready for use. after removing the overwrap, check for minute leaks by squeezing container firmly. if leaks are found, discard solution as sterility may be impaired. not made with natural rubber latex, pvc or dehp. rx only excel is a registered trademark of b. braun medical inc. b. braun medical inc. bethlehem, pa 18018-3524 usa 1-800-227-2862 www.bbraun.com in canada, distributed by: b. braun of canada, ltd. scarboough, ontario m1h 2w4 y94-003-223 ld-136-4 exp lot other 250 ml container label l8002

Principal display panel - 0.45 g/1000 ml container label 0.45% sodium chloride injection usp ref l8020 ndc 0264-7802-00 din 01927949 hk 22616 1000 ml excel ® container each 100 ml contains: sodium chloride usp 0.45 g; water for injection usp qs ph adjusted with hcl nf ph: 5.6 (4.5-7.0); calc. osmolarity: 155 mosmol/liter, hypotonic electrolytes (meq/liter): na + 77; cl – 77 sterile, nonpyrogenic. single dose container. do not use in series connection. for intravenous use only. use only if solution is clear and container and seals are intact. warnings: some additives may be incompatible.consult with pharmacist. when introducing additives, use aseptic techniques. mix thoroughly. do not store. recommended storage: room temperature (25°c). avoid excessive heat. protect from freezing. see package insert. do not remove overwrap until ready for use. after removing the overwrap, check for minute leaks by squeezing container firmly. if leaks are found, discard solution as sterility may be impaired. not made with natural rubber latex, pvc or dehp. rx only excel is a registered trademark of b. braun medical inc. b. braun medical inc. bethlehem, pa 18018-3524 usa 1-800-227-2862 www.bbraun.com in canada, distributed by: b. braun of canada, ltd. scarborough, ontario m1h 2w4 y94-003-230 ld-135-3 exp lot other 1000 ml container label l8020

Principal display panel - 0.45 g/500 ml container label 0.45% sodium chloride injection usp ref l8021 ndc 0264-7802-10 din 01927949 hk 22616 500 ml excel ® container each 100 ml contains: sodium chloride usp 0.45 g; water for injection usp qs ph adjusted with hcl nf ph: 5.6 (4.5-7.0); calc. osmolarity: 155 mosmol/liter, hypotonic electrolytes (meq/liter): na + 77; cl – 77 sterile, nonpyrogenic. single dose container. do not use in series connection. for intravenous use only. use only if solution is clear and container and seals are intact. warnings: some additives may be incompatible. consult with pharmacist. when introducing additives, use aseptic techniques. mix thoroughly. do not store. recommended storage: room temperature (25°c). avoid excessive heat. protect from freezing. see package insert. do not remove overwrap until ready for use. after removing the overwrap, check for minute leaks by squeezing container firmly. if leaks are found, discard solution as sterility may be impaired. not made with natural rubber latex, pvc or dehp. rx only excel is a registered trademark of b. braun medical inc. b. braun medical inc. bethlehem, pa usa 18018-3524 1-800-227-2862 www.bbraun.com in canada, distributed by: b. braun of canada, ltd. scarborough, ontario m1h 2w4 y94-003-227 ld-134-4 exp lot other 500 ml container label l8021


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.